Only limited data are available concerning the long-term outcomes of imatinib treatment among Vietnamese or Asian patients with unresectable or recurrent gastrointestinal stromal tumors (GISTs). Our study, which was conducted in 188 patients, aimed to assess the efficacy of imatinib mesylate against unresectable or recurrent GISTs. Imatinib had a high response rate and long survival. Some predictors favorable for progression-free survival and overall survival are good performance status and response with imatinib. Findings are discussed in relation to clinical practice in low- and middle-income country.
unplanned hospital admissions, both at 90 and 180 days. Treatment differences were analyzed using two sample t-test and chi-square test. Overall survival was evaluated at 180 days, and by Kaplan-Meier and log-rank test and was calculated from first day of radiation therapy. Results: 29 patients received chemoRT and 28 received SMART. Median follow up for the chemoRT group was 294 days and for SMART was 185 days. Groups did not have significant differences in age, performance status, stage, gender, CA 19-9, or neoadjuvant chemotherapy. Grade 3+ GI toxicity at 90 days was seen in 28% and 11% (p Z 0.11) in the chemoRT and SMART groups, respectively. Types of toxicity were overall comparable with most being abdominal pain and duodenal bleeds. Hospital admissions at 90 days occurred in 38% and 21% of patients (p Z 0.17) and at 180 days in 33% and 44% (p Z 0.48). Surgical resection was achieved in 24% of chemoRT and 36% of SMART patients (p Z 0.34). When evaluated using Kaplan-Meier and log-rank test there was a trend to overall survival benefit in the SMART group (p Z 0.07). There was also a statistically significant 180-day survival improvement in SMART patients of 94% vs 70% in chemoRT patients (p Z 0.046). Conclusion: Dose escalated SMART for locally advanced and borderline pancreatic cancer does not cause significant increase in GI grade 3+ GI toxicity at 90 days or hospitalization at 90 or 180 days as compared to chemoRT. Dose escalated SMART appears to be both safe and effective in our urban population. OS in the chemoRT group was comparable to previous trials such as LAP07. There is a trend to OS improvement on Kaplan-Meier analysis in the SBRT group (p Z 0.07), as well as statistically significant improvement in 180-day survival; which supports the ongoing multi-institutional SMART study (NCT03621644). Updated results to be presented at the meeting.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.